Qualcomm (QCOM) reported $12.25 billion in revenue for the quarter ended December 2025, representing a year-over-year increase of 5%. EPS of $3.50 for the same period compares to $3.41 a year ago.The reported revenue represents a surprise of -0.26% over the Zacks Consensus Estimate of $12.28 billion. With the consensus EPS estimate being $3.39, the EPS surprise was +3.15%.While investors scrutinize revenue and earnings changes year-over-year and how they compare with Wall Street expectations to determine th ...

RT Ekubo (@EkuboProtocol)The DAO is now earning 2× more than it spends on incentives!After replacing LP withdrawal fees with a nominal swap fee, Ekubo revenue surged, generating $10k+ in fees last week alone (annualizing to ~$500k from Starknet alone, all used for Ekubo buybacks). https://t.co/Tx8yUdgfln ...

Alphabet Beats Earnings Expectations As Annual Revenue Tops $400 Billion For First Timehttps://t.co/oimVJBtbYQ https://t.co/fBMkieyI5i ...

Related:@HyperliquidX made ~$250 million in revenue in Q4 '25Perps ($233.8m), Spot ($11.5m), and L1 ($3.7m)https://t.co/72TL890JwJ https://t.co/RizCBzP3tRWill Price (@will__price):Some takeaways from the new blockworks Lighter dashboard:1) Hyperliquid has 3.3x the DAUs of Lighter https://t.co/eFTD3U2if5 ...

Core Viewpoint - Tapestry, Inc. is a prominent player in the retail apparel and shoes industry, recognized for its luxury brands and strategic growth initiatives [1] Earnings Expectations - Tapestry is scheduled to release its quarterly earnings report on February 5, 2026, with analysts forecasting an earnings per share (EPS) of $2.20 and revenue of approximately $2.32 billion [2][6] Historical Performance - The company has a track record of exceeding earnings estimates, with a recent average surprise of 6.69% and a notable earnings report last quarter where it achieved $1.38 per share against a consensus estimate of $1.25, resulting in a 10.40% surprise [3][4][6] Financial Health - Tapestry's financial metrics include a high P/E ratio of 101.50, a price-to-sales ratio of 3.69, and an enterprise value to sales ratio of 4.17, indicating strong market valuation. The debt-to-equity ratio stands at 10.51, reflecting significant reliance on debt, while the current ratio of 1.52 suggests sufficient liquidity to meet short-term obligations [5][6]

Core Insights - Techne (TECH) reported revenue of $295.88 million for the quarter ended December 2025, reflecting a slight decline of 0.4% year-over-year, while EPS increased to $0.46 from $0.42 in the previous year [1] - The revenue exceeded the Zacks Consensus Estimate of $292.03 million by 1.32%, and the EPS surpassed the consensus estimate of $0.43 by 8.24% [1] Financial Performance - Organic Growth in Diagnostics and Spatial Biology was reported at 3%, slightly below the average estimate of 3.9% from two analysts [4] - Organic Growth in Protein Sciences showed a decline of 1%, outperforming the estimated decline of 2.2% [4] - Net Sales for Diagnostics and Spatial Biology reached $81.18 million, close to the average estimate of $81.4 million from three analysts [4] - Net Sales for Protein Sciences amounted to $215.08 million, exceeding the average estimate of $207.1 million, representing a year-over-year increase of 1.7% [4] - Intersegment revenue reported a loss of $0.39 million, better than the average estimate of a loss of $0.45 million, but showed a significant year-over-year decline of 23.2% [4] Market Performance - Over the past month, Techne's shares returned -1%, contrasting with the Zacks S&P 500 composite's increase of 0.9% [3] - The stock currently holds a Zacks Rank 4 (Sell), indicating potential underperformance relative to the broader market in the near term [3]

Core Viewpoint - Abbott Laboratories has experienced significant stock underperformance compared to the broader market and key sector indices, raising concerns about its growth outlook and performance in critical segments [2][3][6]. Company Overview - Abbott Laboratories, with a market cap of $189.6 billion, operates globally in healthcare, focusing on pharmaceuticals, diagnostics, nutrition, and medical devices [1]. Stock Performance - Over the past 52 weeks, Abbott's stock has decreased by 15.1%, while the S&P 500 Index has gained 15.4% [2]. - Year-to-date, Abbott's stock has declined nearly 13%, contrasting with a 1.1% rise in the S&P 500 [2]. Segment Performance - In Q4 2025, Abbott reported revenue of $11.46 billion, missing Wall Street estimates, with adjusted EPS of $1.50 meeting expectations [6]. - Key segments showed weak performance: Nutrition sales fell by 8.9% reported (9.1% organic), and Diagnostics declined by 2.5% reported, attributed to lower volumes and reduced COVID-19 testing demand [6]. Growth Outlook - Abbott's organic sales growth outlook for 2026 is projected at 6.5% - 7.5%, which is below prior consensus expectations, contributing to investor concerns [6]. - For the fiscal year ending December 2026, analysts expect adjusted EPS to grow by 10.3% year-over-year to $5.68 [7]. Analyst Ratings - Among 28 analysts covering Abbott, the consensus rating is a "Strong Buy," with 20 "Strong Buy" ratings, two "Moderate Buys," and six "Holds" [7]. - Wells Fargo analyst lowered Abbott's price target to $122 while maintaining an "Overweight" rating, with a mean price target of $134.38 indicating a 23.3% premium to the current price [8].

Core Viewpoint - Reinsurance Group of America (RGA) is a significant player in the reinsurance industry, with upcoming quarterly earnings expected to show positive growth in earnings per share (EPS) and revenue, reflecting a favorable outlook from analysts [1][5]. Financial Performance Expectations - RGA is set to release its quarterly earnings on February 5, 2026, with analysts estimating an EPS of $5.86 and projected revenue of approximately $6.25 billion [1]. - The consensus EPS estimate has been revised upward by 0.6% over the past 30 days, indicating a positive reassessment by analysts [1][5]. Market Valuation Metrics - RGA has a price-to-earnings (P/E) ratio of approximately 15.44 and a price-to-sales ratio of about 0.60, reflecting the market's valuation relative to its revenue [3]. - The enterprise value to sales ratio is around 0.65, and the enterprise value to operating cash flow ratio is approximately 2.98 [3]. - The earnings yield for RGA is about 6.48%, indicating the earnings generated per dollar invested in the company's stock [4]. Financial Health Indicators - RGA's debt-to-equity ratio is approximately 0.44, suggesting a moderate level of debt relative to equity [4].

Core Viewpoint - Rockwell Automation is expected to report strong quarterly earnings, with significant growth in both EPS and revenue, reflecting the company's operational excellence and market confidence [2][3][6] Financial Performance - Earnings Per Share (EPS) is projected to be $2.54, indicating a 38.8% increase from the previous year [2][6] - Anticipated revenue is $2.09 billion, representing a 10.9% year-over-year growth, driven by strategic pricing and effective supply-chain actions [2][6] Market Expectations - Wall Street analysts have shown growing confidence in Rockwell Automation, with a 1.2% upward revision in EPS estimates over the past 60 days [2] - The company has a history of exceeding Zacks Consensus Estimates, with an average earnings surprise of 12.3% over the last four quarters [3][6] Valuation Metrics - Rockwell Automation has a Price-to-Earnings (P/E) ratio of 55.96, indicating that investors are willing to pay a premium for its earnings [4] - The Price-to-Sales ratio stands at 5.80, and the Enterprise Value to Sales ratio is 6.18, reflecting the market's assessment of the company's revenue streams and overall worth [4] Financial Health - The company maintains a debt-to-equity ratio of nearly 1.00 and a current ratio of 1.14, suggesting a balanced approach to financing and the ability to cover short-term liabilities [5]

Core Viewpoint - McKesson Corporation is positioned as a leading healthcare services and information technology company, with strong anticipated earnings growth and revenue increase for the upcoming quarter [1][2]. Financial Performance - Analysts expect McKesson to report earnings per share (EPS) of $9.31, reflecting a 15.9% increase from the previous year [2][6]. - Revenue is projected to reach $105.54 billion, marking a 10.8% rise from the same quarter last year [2][6]. - The consensus EPS estimate has remained unchanged over the past 30 days, indicating strong analyst confidence in the company's performance [3][6]. Valuation Metrics - The price-to-earnings (P/E) ratio is 26.03, suggesting that investors are willing to pay a premium for the company's earnings [4][6]. - The price-to-sales ratio is 0.27 and the enterprise value to sales ratio is 0.29, indicating a reasonable valuation relative to sales [4]. - The enterprise value to operating cash flow ratio is 16.16, showcasing the company's cash flow generation capabilities [4]. Capital Structure and Liquidity - The earnings yield stands at 3.84%, providing insight into the return on investment [5][6]. - A negative debt-to-equity ratio of -5.63 indicates a unique capital structure that may require further analysis [5][6]. - The current ratio is 0.88, suggesting potential liquidity considerations as it is below the ideal level of 1.0 [5].